Annular mesh
09770348 · 2017-09-26
Assignee
Inventors
Cpc classification
A61F2/90
HUMAN NECESSITIES
A61F2/915
HUMAN NECESSITIES
A61F2/86
HUMAN NECESSITIES
A61F2002/91583
HUMAN NECESSITIES
A61F2/92
HUMAN NECESSITIES
A61F2002/91508
HUMAN NECESSITIES
A61F2/89
HUMAN NECESSITIES
A61F2002/91516
HUMAN NECESSITIES
A61F2/91
HUMAN NECESSITIES
A61F2/04
HUMAN NECESSITIES
A61F2/88
HUMAN NECESSITIES
International classification
A61F2/92
HUMAN NECESSITIES
A61F2/91
HUMAN NECESSITIES
A61F2/89
HUMAN NECESSITIES
Abstract
An annular mesh expandable radially from a compact diameter to a radially-expanded deployed disposition in which the mesh is capable of sustaining a radially outwardly directed resistive force even when flexing its longitudinal axis out of a straight line, the mesh being composed of stenting struts, the stenting struts being arranged in a plurality of zig-zag strings around the circumference of the lumen, with occasional connector struts joining adjacent strings to create a closed circumference unit cell between two such connector struts and two adjacent connected strings there being a plurality of such unit cells arranged in sequence around the circumference between said two adjacent strings; and characterized in that there is a non-constant increment of strut length, serving to displace along the longitudinal axis each unit cell relative to the circumferentially next adjacent unit cell.
Claims
1. An annular mesh that defines a longitudinal lumen wherein the mesh is radially expandable from a predeployment disposition to a radially expanded deployed disposition in which the mesh is adapted to direct a resistive force radially outward while simultaneously flexing in response to externally applied bowing forces, the mesh comprises stenting struts arranged in a plurality of zig-zag strings around a lumen circumference, with connector struts joining adjacent strings of stenting struts at an apex of each of the adjacent strings of stenting struts to create a closed circumference unit cell between two adjacent connector struts and two adjacent connected strings of stenting struts, a plurality of the unit cells are arranged around the lumen between two strings of stenting struts, and a portion of a zig-zag string defined between adjacent connector struts defining a portion of the unit cell, the portion of the zig-zag string defining three strut lengths, two of the strut lengths exhibit a constant strut length, and a third strut length exhibits a non-constant strut length that displaces longitudinally adjacent unit cells circumferentially about the longitudinal axis.
2. The mesh according to claim 1 wherein the mesh forms a stent adapted for use in a body lumen of a human or animal.
3. The mesh according to claim 2 wherein the length of the struts of each of the connected strings of stenting struts is constant, except for one strut in the portion of each of the two adjacent connected strings of stenting struts, which is shorter than the other struts of the portion.
4. The mesh according to claim 2 wherein the length of the struts of each of the connected strings of stenting struts is constant, except for two struts in the portion of each of the two adjacent connected strings of stenting struts that are shorter than the other struts of the portion.
5. The mesh according to claim 4 wherein the increment of strut length of each of the connected strings of stenting struts is constant, except for an axial offsetting increment that lies between a single adjacent pair of struts wherein the offsetting increment is different from the constant increment.
6. The mesh according to claim 5 wherein the constant increment is constant, except for an axial offsetting increment that lies between two adjacent pairs of struts of the portion that is different from the constant increment, and not necessarily the same for both of the two adjacent pairs of struts.
7. The mesh according to claim 1 in which the mesh of struts is compatible with manufacture out of a seamless tube, by slitting the tube, through its wall thickness with a multiplicity of slits.
8. The mesh according to claim 7 wherein most or all of the slits are straight.
9. The mesh according to claim 8 wherein some of the straight slits are parallel to the longitudinal axis.
10. The mesh according to claim 8 wherein the connector struts are also formable by slitting the tube.
11. The mesh according to claim 10 wherein connector struts are straight.
12. The mesh according to claim 11 wherein the straight connector struts are parallel to the longitudinal axis.
13. The mesh according to claim 1 wherein the connected strings of stenting struts include peaks that are disposed in a facing relationship in the compact pre-deployment disposition peak to peak, and wherein upon radial expansion to the deployed disposition the peaks of the stenting struts move circumferentially away from the facing relationship into a non-facing relationship thereby enhancing a bending flexibility of the expanded mesh.
14. The mesh according to claim 1 wherein each string of stenting struts exhibits a plurality of circumferentially spaced apart three leg nodes, where a connector strut merges with the string, the portion of the string between two such nodes being oriented perpendicular to the longitudinal axis, where the strings advance axially along the longitudinal axis.
15. The mesh according to claim 14 wherein the closed circumference of each unit cell includes six nodes.
16. The mesh according to claim 1 wherein the unit cells on a first axial side of a string and the unit cells on a second axial side of the string are alike.
17. The mesh according to claim 1 wherein the unit cells on a first axial side of a string are of one form, and the unit cells on a second axial side of the string are of another form.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
DETAILED DESCRIPTION
(7) It is convenient, for two dimensional drawing sheets, representing an annular mesh matrix, to open the matrix out and lay it flat on the plane of the drawing sheet. This has been done, in each of the accompanying drawing
(8) Looking first at drawing
(9) The connector struts 18 and 20 that connect zig-zag strings B and C are circumferentially staggered relative to the struts 10, 12, 14 and 16 that make up parts of the periphery of the unit cells in the next adjacent stenting loops, formed by strings A and B and strings C and D respectively. There are two unit cells U1 lying between zig-zag string B and zig-zag string C. One of those unit cells is evident, in full, in
(10) The drawing shows the annulus in a radially expanded disposition, ready to resist radially inwardly directed forces tending to reduce the diameter of the lumen surrounded by the annular mesh. Supposing that the mesh is representative of the strut matrix of a transluminally delivered stent, one can imagine the disposition of the struts shown in
(11) It will be evident that the design shown in
(12) Also evident from
(13) Turning to
(14) The design of
(15) The view from any unit cell U4, looking along the longitudinal axis of the annulus, is of other unit cells U4, located (in the drawing) due East and due 1 Jest of the viewing position, without any circumferential stagger towards the North or the South. Nevertheless, by virtue of the different length struts, any particular peak point of inflection 46 faces in the longitudinal direction of the annulus a valley 48 between two struts 50 and 52 of the next adjacent unit cell linked by the connector strut 40. Thus, the arrangement of unit cells and connector struts is relatively simple (all struts are cut straight) yet the “peak-to-valley” configuration in the radially expanded disposition shown in
(16) It will also be appreciated by skilled readers that although struts 40 are on a line that slants relative to the longitudinal axis of the annulus, when the mesh is in the expanded disposition as shown in
(17) Finally, the unit cell of
(18) It will be appreciated that the unit cells of
(19) Although the various unit cells of
(20) Attention is now directed to drawing
(21) Looking at
(22) Overall, the matrix displays a slanting or helical pattern, in that each sequence of stenting struts alternating with points of inflection 114, is seen to lie between notional slanting lines S1 and S2 that lie at an acute angle to the longitudinal axis of the matrix. By contrast, a so-called “ring stent” would display stenting rings between two notional lines that are perpendicular to the longitudinal axis of the stent.
(23) Each of the inclined zig-zag stenting loops is joined to the adjacent stenting loop by connector struts 116 that are seen to have a circumferential width of 2 W and that extend across the slanting lines S1 and S2 with a length direction parallel to the long axis of the stent. As can be see, there are four such connector struts 116 in each turn of the stenting loop around the axis of the matrix. It is part of the advantage of the invention that it can yield stents with a high flexibility even through stenting loops are connected by a plurality of simple short straight axial connectors.
(24) It can also be seen that there are “holes” 118 in the matrix, that is, through apertures in the stent wall, of substantial open area, even in the as cut matrix, which holes also span the slant line S1, S2 and lie between two adjacent stenting loops. These holes 118 arise during the laser cutting of the stent matrix, after the laser has cut all around the periphery of hole 118. See our own earlier WO 2001/032102 for a description of the creation of similar holes.
(25) Importantly, each stenting loop 120 that lies between two slanting lines, for example 81 and 82, exhibits loop portions with a constant length of laser cut 112 and stenting strut 110. Furthermore, these cuts, struts and points of inflection 114 present an appearance of part of a ring stent with its stenting loops perpendicular to the long axis of the stent. They are interspersed by occasional, shorter than usual struts 122 that are contiguous with a connector strut 116. The skilled reader will appreciate that the response of a strut to any particular applied bending stress depends on the length of that strut.
(26) Before leaving
(27) Moving to
(28) Turning now to drawing
(29) Notably, the presence of distinct “holes” 118, in
(30) It should also be noted that the huge increase in circumferential length, on moving from the as cut configuration of
(31)
(32) We see in the strut matrix a plurality of nodes 160, where three struts end, one of which is a connector strut 116. In this embodiment each node 160 is also a point of inflection 114 between a regular stenting strut 110 and one of the occasional shorter struts 122.
(33) Let us examine the zig-zag string of stenting struts that includes the three leg nodes 160A, B, C and D. Each portion of the zig-zag string, between any two adjacent nodes A-B, B-C, C-D, is a portion of a stenting ring that is orientated perpendicular to the stent axis. Each circumferential portion A to B, B to C, C to D is axially stepwise offset from its neighbor portions, the step occurring at the three leg node.
(34) The same can be discerned in the other drawing figures but the schematic representation of
(35) Looking at
(36) The stent strut matrix designs of the present invention lend themselves to covered stent embodiments, such as stent grafts. The “holes” 118 can offer good possibilities for bonding together, across the stent wall, films or membranes (such as of expanded PTFE) that lie radially within and outside the stent annulus. The state of the art is replete with teachings how to apply coatings to stents but a stent matrix in accordance with this invention offers possibilities not available with prior art stent strut matrices.
(37) The layout of struts in the real life expanded configuration (such as shown in
(38) Finally we turn to
(39) By contrast, the “knight” chess piece follows a distinctive path that can be characterized as “two steps forward and one step across” (the knight has other possibilities such as “two steps across followed by one step backwards” but for the purposes of the present description we need not concern ourselves with these other possibilities. Important to stress is that the present invention seeks to take the best of both the ring stent and the spiral stent, and to do this by building stenting loops that, in one sense, advance around the circumference in a direction perpendicular to the stent axis while, in another sense, spiraling around the lumen. To do this, the zig-zag loops can advance for a circumferential portion perpendicular to the axis and then step axially sideways, before resuming their advance, for another small portion of the circumference, perpendicular to the longitudinal axis of the annulus. See
(40) The aim to achieve the “best of both worlds” is of course to achieve the radial force of a ring stent with the flexibility of a spiral stent. Intuitively, one can see from
(41) In this way, stents according to the present invention offer the possibility of achieving, simultaneously, both a high radial stenting force and a high tolerance of bending after placement in the body.
(42) Where undulations are embodied in the form of zig-zag struts, the zig-zag struts may include a repeating pattern made of a unit of four generally linear members that extend oblique to the longitudinal axis to intersect each other at three apices spaced apart circumferentially and axially. Also, the prosthesis can utilize not only the circumferential bridges but also other bridge configurations in combination. Alternatively, the bridge directly connects a peak of one circumferential section to another peak of an adjacent circumferential section. In yet another alternative, the bridge may connect a peak of one circumferential section to a trough of an adjacent circumferential section. In a further alternative, the bridge can connect a trough of one circumferential section to a trough of an adjacent circumferential section. Moreover, the undulations can be wave-like in pattern. The wave-like pattern can also be generally sinusoidal in that the pattern may have the general form of a sine wave, whether or not such wave can be defined by a mathematical function. Alternatively, any wave-like forms can be employed so long as it has amplitude and displacement. For example, a square wave, saw tooth wave, or any applicable wave-like pattern defined by the struts where the struts have substantially equal lengths or unequal lengths. And as used herein, the term “implantable prosthesis” is intended to cover not only a bare stent but also coated, covered, encapsulated, bio-resorbable stent or any portion of similar stents.
(43) Bio-active agents can be added to the prosthesis (e.g., either by a coating or via a carrier medium such as resorbable polymers) for delivery to the holt's vessel or duct. The bio-active agents may also be used to coat the entire stent. A material forming the stent or coupled to the stent may include one or more (a) non-genetic therapeutic agent, (b) genetic materials, (c) cells and combinations thereof with (d) other polymeric materials.
(44) (a) Non-genetic therapeutic agents include anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents such as enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, antithrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; vascular cell growth promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vascoactive mechanisms.
(45) (b) Genetic materials include anti-sense DNA and RNA, DNA coding for, anti-sense RNA, tRNA or rRNA co replace defective or deficient endogenous molecules, angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor epidermal growth factor, transforming growth factor alpha and beta, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor and insulin like growth factor, cell cycle inhibitors including CD inhibitors, thymidine kinase (“TK”) and other agents useful for interfering with cell proliferation the family of bone morphogenic proteins (“BMP's”}, BlVfiP-2, BMP-3, BJYIP-4, BMP-5, BT-iP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-1, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Desirable BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules.
(46) Alternatively or, in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the “hedgehog” proteins, or the DNA's encoding them.
(47) (c) Cells can be of human origin (autologous or allogeneic) or from an animal source (xenogeneic), genetically engineered if desired to deliver proteins of interest at the deployment site. The cells may be provided in a delivery media. The delivery media may be formulated as needed to maintain cell function and viability.
(48) (d) Suitable polymer materials as a coating or the base material may include polycarboxylic acids, cellulosic polymers, including cellulose acetate and cellulose nitrate, gelatin, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyanhydrides including maleic anhydride polymers, polyamides, polyvinyl alcohols, copolymers of vinyl monomers such as EVA, polyvinyl ethers, polyvinyl aromatics, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters including polyethylene terephthalate, polyacrylamides, polyethers, polyether sulfone, polycarbonate, polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene, halogenated polyalkylenes including polytetrafluoroethylene, polyurethanes, polyorthoesters, proteins, polypeptides, silicones, siloxane polymers, polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate valerate and blends and copolymers thereof, coatings from polymer dispersions such as polyurethane dispersions (for example, BAYHDROL® fibrin, collagen and derivatives thereof), polysaccharides such as celluloses, starches, dextrans, alginates and derivatives, hyaluronic acid, squalene emulsions. Polyacrylic acid, available as HYDROPLUS® (Boston Scientific Corporation, Natick, Mass.), and described in U.S. Pat. No. 5,091,205, the disclosure of which is hereby incorporated herein by reference, is particularly desirable. Even more desirable is a copolymer of polylactic acid and polycaprolactone.
(49) While the invention has been described in terms of particular variations and illustrative figures, those of ordinary skill in the art will recognize that the invention is not limited to the variations or figures described. In addition, where methods and steps described above indicate certain events occurring in certain order, those of ordinary skill in the art will recognize that the ordering of certain steps may be modified and that such modifications are in accordance with the variations of the invention. Additionally, certain of the steps may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above. Therefore, to the extent there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is the intent that this patent will cover those variations as well. Finally, all publications and patent applications cited in this specification are herein incorporated by reference in their entirety as if each individual publication or patent application were specifically and individually put forth herein.